G
358570
vs
K
KOSPI 200
Over the past 12 months, GI Innovation Inc has underperformed KOSPI 200, delivering a return of -54% compared to KOSPI 200's +146% growth.
Stocks Performance
358570 vs KOSPI 200
Performance Gap
358570 vs KOSPI 200
Performance By Year
358570 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
GI Innovation Inc
Glance View
GI Innovation is a South Korean biopharmaceutical company that discovers and develops drug candidates, with a focus on antibody-based medicines and immune-related therapies. Its work centers on creating new treatments for cancer and other serious diseases, then moving the best candidates through clinical development with partners. The company does not sell a consumer product. It makes money mainly by advancing its drug pipeline, signing research and licensing deals, and partnering with larger pharmaceutical companies that help fund development, testing, and commercialization. In this model, the value comes from proprietary drug assets rather than factories or retail sales. What sets GI Innovation apart is that it sits early in the pharmaceutical value chain, where scientific know-how and intellectual property matter most. Its customers are mainly pharmaceutical partners, research collaborators, and eventually patients through the drug approvals those partners help bring to market.
